tetano
Editor, Senior Moderator
Cell Rep Med
. 2023 Apr 25;101048.
doi: 10.1016/j.xcrm.2023.101048. Online ahead of print. Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccines
Paulina Kaplonek[SUP] 1 [/SUP], Yixiang Deng[SUP] 2 [/SUP], Jessica Shih-Lu Lee[SUP] 1 [/SUP], Heather J Zar[SUP] 3 [/SUP], Dace Zavadska[SUP] 4 [/SUP], Marina Johnson[SUP] 5 [/SUP], Douglas A Lauffenburger[SUP] 6 [/SUP], David Goldblatt[SUP] 7 [/SUP], Galit Alter[SUP] 8 [/SUP]
Affiliations
Despite the successes of current coronavirus disease 2019 (COVID-19) vaccines, waning immunity, the emergence of variants of concern, and breakthrough infections among vaccinees have begun to highlight opportunities to improve vaccine platforms. Real-world vaccine efficacy studies have highlighted the reduced risk of breakthrough infections and diseases among individuals infected and vaccinated, referred to as hybrid immunity. Thus, we sought to define whether hybrid immunity shapes the humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) following Pfizer/BNT162b2, Moderna mRNA-1273, ChadOx1/AZD1222, and Ad26.COV2.S vaccination. Each vaccine exhibits a unique functional humoral profile in vaccination only or hybrid immunity. However, hybrid immunity shows a unique augmentation of S2-domain-specific functional immunity that was poorly induced for the vaccination only. These data highlight the importance of natural infection in breaking the immunodominance away from the evolutionarily unstable S1 domain and potentially affording enhanced cross-variant protection by targeting the more highly conserved S2 domain of SARS-CoV-2.
Keywords: COVID-19; FcR binding; SARS-CoV-2; VOCs; antibody; antibody functions; mRNA vaccine; vaccine; vector vaccine.
. 2023 Apr 25;101048.
doi: 10.1016/j.xcrm.2023.101048. Online ahead of print. Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccines
Paulina Kaplonek[SUP] 1 [/SUP], Yixiang Deng[SUP] 2 [/SUP], Jessica Shih-Lu Lee[SUP] 1 [/SUP], Heather J Zar[SUP] 3 [/SUP], Dace Zavadska[SUP] 4 [/SUP], Marina Johnson[SUP] 5 [/SUP], Douglas A Lauffenburger[SUP] 6 [/SUP], David Goldblatt[SUP] 7 [/SUP], Galit Alter[SUP] 8 [/SUP]
Affiliations
- PMID: 37182520
- DOI: 10.1016/j.xcrm.2023.101048
Despite the successes of current coronavirus disease 2019 (COVID-19) vaccines, waning immunity, the emergence of variants of concern, and breakthrough infections among vaccinees have begun to highlight opportunities to improve vaccine platforms. Real-world vaccine efficacy studies have highlighted the reduced risk of breakthrough infections and diseases among individuals infected and vaccinated, referred to as hybrid immunity. Thus, we sought to define whether hybrid immunity shapes the humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) following Pfizer/BNT162b2, Moderna mRNA-1273, ChadOx1/AZD1222, and Ad26.COV2.S vaccination. Each vaccine exhibits a unique functional humoral profile in vaccination only or hybrid immunity. However, hybrid immunity shows a unique augmentation of S2-domain-specific functional immunity that was poorly induced for the vaccination only. These data highlight the importance of natural infection in breaking the immunodominance away from the evolutionarily unstable S1 domain and potentially affording enhanced cross-variant protection by targeting the more highly conserved S2 domain of SARS-CoV-2.
Keywords: COVID-19; FcR binding; SARS-CoV-2; VOCs; antibody; antibody functions; mRNA vaccine; vaccine; vector vaccine.